Help us build an individualized therapeutic base editing platform to treat St. Jude patients with rare bone marrow failure disorders by correcting their disease-causing mutations in their hematopoietic stem cells in vivo. Dr. Tsai leads the recently launched DRIVE project (Delivering Rare-disease In vivo Editors), funding a multi-institutional, public-private partnership to develop in vivo base editors for treatment of bone marrow failure disorders.
Bring your expertise in genome editing drug development to a Lead Scientist role in the Tsai Lab, where you will help advance genome editing technologies toward individualized treatments for pediatric patients. Our goal is to develop in vivo base editing drug products, complete IND-enabling studies, and open clinical trials in the next 3 years.
About the job opportunity. We are seeking an outstanding and highly motivated Lead Scientist or Senior Scientist to help lead efforts to develop personalized genome editing treatments. We care deeply about the success of our scientists, and this is a unique opportunity to help lead development of an in vivo gene therapeutic gene editing platform and drug products at St. Jude, with substantial room for career growth and advancement.
Overview of our lab. The Tsai lab is a highly collaborative, creative, and motivated group of scientists at St. Jude Children’s Research Hospital. Our research centers on development of state-of-the-art genomic methods for understanding the global activities of genome editors, protein engineering to improve capabilities for precise editing, and translation to autologous genome edited hematopoietic stem cell therapies. Dr. Tsai also co-leads the PARADIGM (Partnership to Advance Development of Individualized Genomic Medicines) blue sky project.
You would have opportunities to lead an exciting and fast-paced drug development effort:
•
Design and develop in vivo base editing drug products to treat St. Jude patients with bone marrow failure disorders.
•
Characterize the genotoxicity of candidate drug products using state-of-the art genomic assays such as CHANGE-seq-BE and CHANCE-seq, including variant-aware analysis.
•
Optimize potency and specificity of a HSC-targeted lipid nanoparticle gene editing approach.
•
Co-lead a multi-disciplinary team to test a new streamlined platform approach for in vivo genome editing medicines.
You would learn valuable skills that include:
•
Genome engineering, high-throughput genomics, laboratory automation, IND-enabling studies for genome editing drug development.